EP300在口腔鳞状细胞癌中的核心角色:调控机制与临床前景

doi:10.13591/j.cnki.kqyx.2026.08.010

摘要/Abstract

摘要：

口腔鳞状细胞癌(oral squamous cell carcinoma, OSCC)是头颈部最为常见的恶性肿瘤,其发生发展涉及多步骤、多基因参与的复杂生物学过程。在这一过程中,表观遗传学调控,尤其是组蛋白修饰,发挥着关键作用。EP300作为一种重要的转录辅激活因子,具有内在组蛋白乙酰转移酶(histone acetyltransferase, HAT)活性,能够通过乙酰化修饰组蛋白及多种非组蛋白,广泛参与染色质结构重塑、基因转录调控、细胞周期进程、DNA损伤修复、细胞分化与凋亡等重要生命活动。近年研究表明,EP300在OSCC中表现出功能上的双重性与复杂性:其功能失调可影响肿瘤的恶性进展;而在某些情境下,其过表达亦可能通过激活不同的致癌信号通路,进而驱动肿瘤生长。本文旨在系统梳理EP300在OSCC中的表达特征、调控机制,并重点阐述其通过与p53、Wnt/β-catenin、Notch、NF-κB等关键信号通路相互作用,参与OSCC发生发展的分子基础。此外,本文还将探讨以EP300及其相关通路为靶点的新型治疗策略在OSCC中的潜力与挑战,并对该领域的未来研究方向作出展望。

关键词: 口腔鳞状细胞癌, EP300, 表观遗传学, 信号通路, 分子靶向治疗

Abstract:

Oral squamous cell carcinoma (OSCC) is the most common malignant tumor of the head and neck region, whose pathogenesis involves a complex, multi-step process with the participation of multiple genes. Epigenetic regulation, particularly histone modifications, plays a critical role in this process. EP300 is a key transcriptional coactivator with intrinsic histone acetyltransferase (HAT) activity. It mediates the acetylation of both histone and non-histone proteins, thereby widely participating in essential biological processes such as chromatin remodeling, gene transcription, cell cycle progression, DNA damage repair, cell differentiation, and apoptosis. Recent studies have revealed a dual and complex role of EP300 in OSCC: while its dysfunction can influence tumor progression, its overexpression may, under certain circumstances, drive tumor growth by activating various oncogenic pathways. This review aims to systematically elucidate the expression status and regulatory mechanisms of EP300 in OSCC, and to elaborate on the molecular mechanisms through which it interacts with multiple signaling pathways (such as p53, Wnt/β-catenin, Notch, and NF-κB) to influence the initiation and progression of OSCC. Furthermore, we will discuss the potential and challenges of targeting EP300 and its related pathways as a novel therapeutic strategy for OSCC, and look into the prospect of future research directions.

Key words: oral squamous cell carcinoma, EP300, epigenetics, signaling pathway, molecular targeted therapy

中图分类号:

R739.85

张超, 韩莉, 刘家宏, 毛周洪, 付浩轩, 唐婉容. EP300在口腔鳞状细胞癌中的核心角色:调控机制与临床前景[J]. 口腔医学, 2026, 46(8): 624-628.

ZHANG Chao, HAN Li, LIU Jiahong, MAO Zhouhong, FU Haoxuan, TANG Wanrong. The central role of EP300 in oral squamous cell carcinoma: Regulatory mechanisms and clinical prospects[J]. Stomatology, 2026, 46(8): 624-628.

参考文献 52

[1]	Gupta R, Strbenac D, Satgunaseelan L, et al. Comparing genomic landscapes of oral and cutaneous squamous cell carcinoma of the head and neck: Quest for novel diagnostic markers[J]. Mod Pathol, 2023, 36(8): 100190. doi: 10.1016/j.modpat.2023.100190
[2]	Sufianov A, Begliarzade S, Kudriashov V, et al. The role of circular RNAs in the pathophysiology of oral squamous cell carcinoma[J]. Noncoding RNA Res, 2023, 8(1): 109-114. doi: 10.1016/j.ncrna.2022.11.004 pmid: 36474750
[3]	Zhang XY, Li QX, Li W, et al. FD-net: Feature distillation network for oral squamous cell carcinoma lymph node segmentation in hyperspectral imagery[J]. IEEE J Biomed Health Inform, 2024, 28(3): 1552-1563. doi: 10.1109/JBHI.2024.3350245
[4]	Ling ZH, Cheng B, Tao XA. Epithelial-to-mesenchymal transition in oral squamous cell carcinoma: Challenges and opportunities[J]. Int J Cancer, 2021, 148(7): 1548-1561. doi: 10.1002/ijc.33352 pmid: 33091960
[5]	Yamana K, Inoue J, Yoshida R, et al. Extracellular vesicles derived from radioresistant oral squamous cell carcinoma cells contribute to the acquisition of radioresistance via the miR-503-3p-BAK axis[J]. J Extracell Vesicles, 2021, 10(14): e12169. doi: 10.1002/jev2.v10.14
[6]	Zhang DZ, Ma BH, Liu DH, et al. Discovery of a peptide proteolysis-targeting Chimera (PROTAC) drug of p300 for prostate cancer therapy[J]. EBioMedicine, 2024, 105: 105212. doi: 10.1016/j.ebiom.2024.105212
[7]	Zeng QM, Wang K, Zhao YX, et al. Effects of the acetyltransferase p300 on tumour regulation from the novel perspective of posttranslational protein modification[J]. Biomolecules, 2023, 13(3): 417. doi: 10.3390/biom13030417
[8]	Xu LX, Xuan HW, Shi XB. Dysregulation of the p300/CBP histone acetyltransferases in human cancer[J]. Epigenomics, 2025, 17(3): 193-208. doi: 10.1080/17501911.2024.2447807 pmid: 39929233
[9]	王亚培, 罗玉春, 刘为, 等. EP300对口腔鳞癌细胞增殖和迁移的影响[J]. 口腔医学, 2024, 44(2): 88-93.
[10]	Bi YH, Kong PZ, Zhang L, et al. EP300 as an oncogene correlates with poor prognosis in esophageal squamous carcinoma[J]. J Cancer, 2019, 10(22): 5413-5426. doi: 10.7150/jca.34261 pmid: 31632486
[11]	Zhang DD, Peng YS, Lin GR, et al. TGF-βRII/EP300/SMAD4 cascade signaling pathway promotes invasion and glycolysis in oral squamous cell carcinoma[J]. J Oral Pathol Med, 2023, 52(6): 483-492. doi: 10.1111/jop.13424 pmid: 36916236
[12]	Fang JY, Yang D, Liu F, et al. EP300/HIF-1 pathway: The key to sacubitril valsartan sodium alleviating myocardial hypoxia injury[J]. Xenobiotica, 2025, 55(6): 478-487. doi: 10.1080/00498254.2025.2528516
[13]	Shi ZL, Zhang H, Shen YM, et al. SETD1A-mediated H3K4me3 methylation upregulates lncRNA HOXC-AS3 and the binding of HOXC-AS3 to EP300 and increases EP300 stability to suppress the ferroptosis of NSCLC cells[J]. Thorac Cancer, 2023, 14(25): 2579-2590. doi: 10.1111/1759-7714.15037 pmid: 37548102
[14]	Ai YL, Wu SY, Zou C, et al. LINC00941 promotes oral squamous cell carcinoma progression via activating CAPRIN2 and canonical WNT/β-catenin signaling pathway[J]. J Cell Mol Med, 2020, 24(18): 10512-10524. doi: 10.1111/jcmm.v24.18
[15]	Zeng YQ, Zhou Y, Ruan JY, et al. EP300 compromises antitumor immunity by increasing SOCS1 expression[J]. J Immunother Cancer, 2025, 13(10): e011488. doi: 10.1136/jitc-2025-011488
[16]	Wen LZ, Xie B, Li H, et al. EP300 through upregulating the expression of vimentin to promote the progression of chordoma[J]. Neurosurg Focus, 2024, 56(5): E17.
[17]	Miao Y, Medeiros LJ, Xu-Monette ZY, et al. Dysregulation of cell survival in diffuse large B cell lymphoma: Mechanisms and therapeutic targets[J]. Front Oncol, 2019, 9: 107. doi: 10.3389/fonc.2019.00107 pmid: 30881917
[18]	Luo MY, Zhang YF, Xu ZF, et al. Experimental analysis of bladder cancer-associated mutations in EP300 identifies EP300-R1627W as a driver mutation[J]. Mol Med, 2023, 29(1): 7. doi: 10.1186/s10020-023-00608-7 pmid: 36647005
[19]	Lapke N, Lu YJ, Liao CT, et al. Missense mutations in the TP53 DNA-binding domain predict outcomes in patients with advanced oral cavity squamous cell carcinoma[J]. Oncotarget, 2016, 7(28): 44194-44210. doi: 10.18632/oncotarget.9925 pmid: 27283772
[20]	Irimie AI, Braicu C, Pileczki V, et al. Knocking down of p53 triggers apoptosis and autophagy, concomitantly with inhibition of migration on SSC-4 oral squamous carcinoma cells[J]. Mol Cell Biochem, 2016, 419(1/2): 75-82. doi: 10.1007/s11010-016-2751-9
[21]	Zeng YF, Kong Y, Liao L, et al. Involvement of RUVBL1 in WNT/β-catenin signaling in oral squamous cell carcinoma[J]. Dis Markers, 2022, 2022: 3398492.
[22]	Koopmans T, Eilers R, Menzen M, et al. β-Catenin directs nuclear factor-κB p65 output via CREB-binding protein/p300 in human airway smooth muscle[J]. Front Immunol, 2017, 8: 1086. doi: 10.3389/fimmu.2017.01086 pmid: 28943877
[23]	Sun YH, Sun J, Ying KJ, et al. EP300 regulates the SLC16A1-AS1-AS1/TCF3 axis to promote lung cancer malignancies through the Wnt signaling pathway[J]. Heliyon, 2024, 10(6): e27727. doi: 10.1016/j.heliyon.2024.e27727
[24]	Zhu XF, Li YS, Shao ZY, et al. NAP1L1 promotes endometrial cancer progression via EP300-mediated DDX5 promoter acetylation[J]. Mol Cancer Res, 2024, 22(11): 1011-1021. doi: 10.1158/1541-7786.MCR-23-0871
[25]	Su Y, Zhou Y, Sun YJ, et al. Macrophage-derived CCL18 promotes osteosarcoma proliferation and migration by upregulating the expression of UCA1[J]. J Mol Med (Berl), 2019, 97(1): 49-61. doi: 10.1007/s00109-018-1711-0 pmid: 30426155
[26]	Su YQ, Lian JM, Chen SY, et al. Epigenetic histone acetylation modulating prenatal Poly I: C induced neuroinflammation in the prefrontal cortex of rats: A study in a maternal immune activation model[J]. Front Cell Neurosci, 2022, 16: 1037105. doi: 10.3389/fncel.2022.1037105
[27]	Di Pietrantonio N, Di Tomo P, Mandatori D, et al. Diabetes and its cardiovascular complications: Potential role of the acetyltransferase p300[J]. Cells, 2023, 12(3): 431. doi: 10.3390/cells12030431
[28]	Lee HH, Sanada S, An SM, et al. LPS-induced NFκB enhanceosome requires TonEBP/NFAT5 without DNA binding[J]. Sci Rep, 2016, 6: 24921. doi: 10.1038/srep24921 pmid: 27118681
[29]	Kong FY, Ma LH, Wang X, et al. Regulation of epithelial-mesenchymal transition by protein lysine acetylation[J]. Cell Commun Signal, 2022, 20(1): 57. doi: 10.1186/s12964-022-00870-y pmid: 35484625
[30]	Zhou JP, Tao DT, Xu Q, et al. Expression of E-cadherin and vimentin in oral squamous cell carcinoma[J]. Int J Clin Exp Pathol, 2015, 8(3): 3150-3154.
[31]	Chen HT, Liu H, Mao MJ, et al. Crosstalk between autophagy and epithelial-mesenchymal transition and its application in cancer therapy[J]. Mol Cancer, 2019, 18(1): 101. doi: 10.1186/s12943-019-1030-2
[32]	Saitoh M. Epithelial-mesenchymal transition is regulated at post-transcriptional levels by transforming growth factor-β signaling during tumor progression[J]. Cancer Sci, 2015, 106(5): 481-488. doi: 10.1111/cas.2015.106.issue-5
[33]	Chanda A, Sarkar A, Deng LL, et al. Sumoylated SnoN interacts with HDAC1 and p300/CBP to regulate EMT-associated phenotypes in mammary organoids[J]. Cell Death Dis, 2023, 14(7): 405. doi: 10.1038/s41419-023-05921-x pmid: 37414747
[34]	Shi QM, Xue C, Zeng YF, et al. Notch signaling pathway in cancer: From mechanistic insights to targeted therapies[J]. Signal Transduct Target Ther, 2024, 9(1): 128.
[35]	Oswald F, Täuber B, Dobner T, et al. p300 acts as a transcriptional coactivator for mammalian Notch-1[J]. Mol Cell Biol, 2001, 21(22): 7761-7774. pmid: 11604511
[36]	Kondratyev M, Pesic A, Ketela T, et al. Identification of acquired Notch3 dependency in metastatic Head and Neck Cancer[J]. Commun Biol, 2023, 6(1): 538. doi: 10.1038/s42003-023-04828-9 pmid: 37202533
[37]	Li RF, Yu L, Xu MC, et al. Androgen receptor governs tip cell formation in cerebrovascular malformations[J]. Circ Res, 2025, 137(5): 628-645. doi: 10.1161/CIRCRESAHA.125.326471 pmid: 40641462
[38]	Jiang XH, Ye J, Dong ZH, et al. Novel genetic alterations and their impact on target therapy response in head and neck squamous cell carcinoma[J]. Cancer Manag Res, 2019, 11: 1321-1336. doi: 10.2147/CMAR.S187780 pmid: 30799957
[39]	Li CN, Wu PJ, Xie XT, et al. Aberrant Notch-signaling promotes tumor angiogenesis in esophageal squamous-cell carcinoma[J]. Signal Transduct Target Ther, 2025, 10(1): 233.
[40]	Chen J, Zhang SH, Huang XM, et al. Sialylated IgG-activated integrin β4-Src-Erk axis stabilizes c-Myc in a p300 lysine acetyltransferase-dependent manner to promote colorectal cancer liver metastasis[J]. Neoplasia, 2025, 61: 101140. doi: 10.1016/j.neo.2025.101140
[41]	Cheng C, He T, Chen K, et al. P300 interacted with N-myc and regulated its protein stability via altering its post-translational modifications in neuroblastoma[J]. Mol Cell Proteomics, 2023, 22(3): 100504. doi: 10.1016/j.mcpro.2023.100504
[42]	Brand M, Clayton J, Moroglu M, et al. Controlling intramolecular interactions in the design of selective, high-affinity ligands for the CREBBP bromodomain[J]. J Med Chem, 2021, 64(14): 10102-10123. doi: 10.1021/acs.jmedchem.1c00348 pmid: 34255515
[43]	Gao SM, Chen M, Wei W, et al. Crosstalk of mTOR/PKM2 and STAT3/c-Myc signaling pathways regulate the energy metabolism and acidic microenvironment of gastric cancer[J]. J Cell Biochem, 2019, 120(2): 1193-1202. doi: 10.1002/jcb.v120.2
[44]	Yang LH, Li JC, Li YZ, et al. Diclofenac impairs the proliferation and glucose metabolism of triple-negative breast cancer cells by targeting the c-Myc pathway[J]. Exp Ther Med, 2021, 21(6): 584. doi: 10.3892/etm.2021.10016 pmid: 33850556
[45]	Yuan J, Peng G, Xiao GL, et al. Xanthohumol suppresses glioblastoma via modulation of Hexokinase 2-mediated glycolysis[J]. J Cancer, 2020, 11(14): 4047-4058. doi: 10.7150/jca.33045
[46]	Kanada R, Kagoshima Y, Suzuki T, et al. Discovery of DS-9300: A highly potent, selective, and once-daily oral EP300/CBP histone acetyltransferase inhibitor[J]. J Med Chem, 2023, 66(1): 695-715. doi: 10.1021/acs.jmedchem.2c01641 pmid: 36572866
[47]	Kanada R, Suzuki T, Murata T, et al. 4-Pyridone-3-carboxylic acid as a benzoic acid bioisostere: Design, synthesis, and evaluation of EP300/CBP histone acetyltransferase inhibitors[J]. Bioorg Med Chem Lett, 2021, 51: 128358. doi: 10.1016/j.bmcl.2021.128358
[48]	Wei W, Song ZH, Chiba M, et al. Analysis and therapeutic targeting of the EP300 and CREBBP acetyltransferases in anaplastic large cell lymphoma and Hodgkin lymphoma[J]. Leukemia, 2023, 37(2): 396-407. doi: 10.1038/s41375-022-01774-z
[49]	Li X, Song YC. Proteolysis-targeting Chimera (PROTAC) for targeted protein degradation and cancer therapy[J]. J Hematol Oncol, 2020, 13(1): 50. doi: 10.1186/s13045-020-00885-3
[50]	Durbin AD, Wang TJ, Wimalasena VK, et al. EP300 selectively controls the enhancer landscape of MYCN^- amplified neuroblastoma[J]. Cancer Discov, 2022, 12(3): 730-751. doi: 10.1158/2159-8290.CD-21-0385
[51]	An SN, Fu LW. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs[J]. E Bio Medicine, 2018, 36: 553-562.
[52]	Zhao JY, Chen HZ, Liang C. Dual functionality of MDM2 in PROTACs expands the horizons of targeted protein degradation[J]. Biomark Res, 2025, 13(1): 111. doi: 10.1186/s40364-025-00826-7 pmid: 40866949